Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients
American Journal of Nephrology · 2023
DOI: 10.1159/000529806 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Cheng-Wen Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Chien Shin hemodialysis center, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Hematinics, Erythropoietin. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear.
Methods
We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0–43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model.
Results
Compared with mean monthly ESA dose of 15,000–25,000 U (mean ± standard deviation 20,609 ± 2,662 U), monthly ESA dose of less than 15,000 U (mean ± standard deviation 7,413 ± 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001–43,000 U (mean ± standard deviation 31,160 ± 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000–25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups.
Conclusions
Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chien Shin hemodialysis center, New Taipei City, Taiwan.
- National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin, Taiwan.
- Department of Public Health, China Medical University, Taichung, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
- Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.
Zitieren
APA
Yang, C. W., Lin, M. C., Shu, K. H., Tung, K. T., Tsai, W. C., Yang, J. Y., Pai, M. F., Wu, H. Y., Chiu, Y. L., Peng, Y. S., Hsu, S. P., Wang, S. H., & Pan, S. Y. (2023). Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients. American Journal of Nephrology. https://doi.org/10.1159/000529806
Vancouver
Yang CW, Lin MC, Shu KH, Tung KT, Tsai WC, Yang JY, et al. Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients. American Journal of Nephrology. 2023. doi:10.1159/000529806
BibTeX
@article{Yang2023,
author = {Yang, Cheng-Wen and Lin, Mei-Chen and Shu, Kai-Hsiang and Tung, Kuei-Tung and Tsai, Wan-Chuan and Yang, Ju-Yeh and Pai, Mei-Fen and Wu, Hon-Yen and Chiu, Yen-Ling and Peng, Yu-Sen and Hsu, Shih-Ping and Wang, Shi-Heng and Pan, Szu-Yu},
title = {Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients},
journal = {American Journal of Nephrology},
year = {2023},
doi = {10.1159/000529806}
}
EUVIMED